immunotherapy

Editor's Page

A Look Into the Future: What`s Next for Pathways?

03/15/2017

Winston Wong, PharmD, Editor-in-Chief

Health care delivery is always in flux, but treatment advances over the last several years have introduced new variables into the health care continuum that were unthinkable even a decade ago. Researchers, providers,...

Health...

03/15/2017

Journal of Clinical Pathways

Research in Review

New Biomarker for Relapsed or Refractory MZL Identified

02/27/2017

JCP Editors

Patients with marginal zone lymphoma (MZL) who underwent prior therapy with an anti-CD20 antibody regimen may be treatable with a tyrosine kinase inhibitor approved for other blood cancers, according to research...

...

02/27/2017

Journal of Clinical Pathways

Research in Review

First-Line Pembrolizumab for NSCLC Improves HRQoL Versus Chemotherapy

12/08/2016

JCP Editors

Patients with early stage metastatic non-small cell lung cancer (NSCLC) whose tumors express high levels of PD-L1 have improved quality of life with pembrolizumab treatment versus standard of care platinum-containing...

...

12/08/2016

Journal of Clinical Pathways

Research in Review

HC-Based Next-Gen Sequencing Aids Treatment Decisions in Lung Cancer

11/23/2016

JCP Editors

Hybrid capture (HC)-based next-generation sequencing (NGS) can identify targetable oncogenic drivers to improve response rates in patients with lung cancer, according to a study published in the Journal of Thoracic...

Hybrid...

11/23/2016

Journal of Clinical Pathways

Quiz

Best Targeted Therapy for Melanoma

11/10/2016

JCP Editors

A study published in JAMA Oncology recently showed that treatment with which of the following drug types was just as effective as BRAF- and MEK-targeted therapies for melanoma and also limited the risk of...

A...

11/10/2016

Journal of Clinical Pathways

Research in Review

TKI Shows Promise in Sarcoma Study

11/10/2016

JCP Editors

Tivozanib was well-tolerated and showed promising antitumor activity in patients with soft tissue sarcoma overexpressing vascular endothelial growth factors (VEGF), supporting efforts for further research, according...

...

11/10/2016

Journal of Clinical Pathways

Research in Review

PD-1 Inhibitors Best Targeted Therapy for Advanced Melanoma

11/08/2016

JCP Editors

A combination of immunotherapy treatments improves survival and lowers the risk of life-threatening events for patients with late-stage melanoma compared with targeted therapy, according to a new JAMA Oncology...

A...

11/08/2016

Journal of Clinical Pathways

Research in Review

CML Mutations Associated With Treatment Failure

10/18/2016

JCP Editors

Somatic mutations may predict treatment failure with tyrosine kinase inhibitors (TKIs) in patients with chronic myeloid leukemia (CML), according to a study published in Blood, the journal of the American Society of...

...

10/18/2016

Journal of Clinical Pathways

Research in Review

Nivolumab Superior to Standard Therapy for Recurrent Head and Neck Cancer

10/14/2016

JCP Editors

Patients with recurrent or metastatic squamous-cell carcinoma of the head and neck may benefit more from treatment with nivolumab than standard, single agent therapy, according to results from a trial published in...

...

10/14/2016

Journal of Clinical Pathways

Department

Biomarker Tied to Immunotherapy Response in Melanoma

09/30/2016

JCP Editors

Researchers at the Perelman School of Medicine, University of Pennsylvania, Philadelphia, have identified a potential biomarker in patients with stage IV melanoma being treated with the immunotherapy...

...

09/30/2016

Journal of Clinical Pathways